A | 컴투스컴투스가 신작 ‘제우스: 오만의 신’ 출시와 함께 닷새 만에 반등에 성공했다.26일 컴투스는 전거래일 대비 8.8% 오른 3만4000원에 정규 장을 마쳤다. 장중 한때 10% 이상 치솟기도 했다. 최근 4거래일 동안은 내림세였다.이날 컴투스는 신작 MMORPG ‘제우스: 오만의 신’을 국내 시장에 출시했다. ‘제우스: 오만의 신’는 넥슨 부사장 출신인 김대훤 대표가 이끄는 에이버튼의 첫 작품으로 관련 업계의 관심을 받아왔다. 이용자 편의성을 극대화한 AI 모드, 상위 이용자 중심의 경쟁 구조 해소를 위해 마련한 AI 캐릭터 ‘페르소나’를 비롯한 각종 장치가 특징이다.‘제우스: 오만의 신’은 출시 전 사전 다운로드만으로 국내 양대마켓 인기순위 1위에 올라 기대감을 입증했다. 출시 첫날 매출 순위는 애플 앱스토어 기준 9위로 데뷔했다. 향후 구글 플레이 매출 순위에 따라 초반 흥행 성과에 대한 평가가 이뤄질 전망이다. 최근 교보증권은 ‘제우스: 오만의 신’의 컴투스에 대한 하반기 매출 기여액을 880억원(평균 일매출 7.7억원)으로 예상하기도 했다.。 CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。
Current article:http://www.rangzhuanhoujuedu.cyou/news/20260826_7071.docx
Published on:04:07:19
